Syamantak Mani Tripathi*, Kamal Kishor, Apoorva Mishra, Asit Jain, Abhishek Meshram, Pramod Sharma and Vandana Gupta

Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science and A.H, Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, India

*Corresponding Author: Syamantak Mani Tripathi, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science and A.H, Jabalpur, Nanaji Deshmukh Veterinary Science University (NDVSU), Jabalpur, Madhya Pradesh, India.

Received: October 25, 2024; Published: November 29, 2024

Abstract

Breast cancer remains a leading cause of cancer-related mortality among women worldwide, highlighting the need for innovative and effective treatment strategies. This review explores advancements in nano-engineered therapeutics aimed at precisely targeting breast cancer cells while overcoming the limitations of conventional therapies. We discuss the heterogeneity of breast tumors, the challenges posed by the tumor microenvironment, and the advantages of utilizing nanoparticles for drug delivery. Recent breakthroughs in nanomedicine, includingveloping liposomal formulations, polymeric nanoparticles, and gold nanoparticles for photothermal therapy, are examined. Additionally, we address the critical imitations of nano-engineered therapeutics, including formulation complexities and regulatory hurdles. By providing a comprehensive overview of the current landscape and future directions in breast cancer treatment, this review is valuable resource for researchers and clinicians seeking to improve patient outcomes.

 Keywords: Breast Cancer; Chemotherapy; Engineered Nano-Therapeutics; Immunotherapy; Liposomes; Micells; Nanorobots; Nanotubes; Radiotherapy; Surgery

References

1. Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians6 (2018): 394-424.
2. International Agency for Research on Cancer. Global Cancer Observatory (2018).
3. Koboldt DC., et al. “Genomic Landscape of Breast Cancer: Insights from Next-Generation Sequencing”. Cancer Research7 (2023): 987-1002.
4. Davis SM., et al. “Emerging Trends in Targeted Therapies for Triple-Negative Breast Cancer”. Journal of Clinical Oncology1 45-60.
5. Kumar P., et al. “Innovative Approaches in Nanotechnology for Breast Cancer Treatment”. Journal of Nanomedicine3 (2024): 150-170.
6. Zhang Y., et al. “Advances in Immunotherapy for Breast Cancer: New Frontiers and Challenges”. Cancer Immunology Research1 (2024): 22-38.
7. Carter P., et al. “Targeted Drug Delivery Systems in Breast Cancer: Innovations and Future Directions”. Pharmacological Reviews2 (2024): 251-269.
8. Siegel RL., et al. “Cancer statistics, 2023”. CA: A Cancer Journal for Clinicians1 (2023): 17-48.
9. Gou J., et al. “Nanoparticle-Mediated Drug Delivery for Targeted Therapy in Breast Cancer: Recent Advances and Future Perspectives”. Journal of Drug Targeting 3 (2024): 345-359.
10. Reddy SS., et al. “Emerging Therapies in Hormone-Receptor Positive Breast Cancer: A Review of Current Clinical Trials”. Breast Cancer Research1 (2024): 78-94.
11. Wang X., et al. “Novel Insights into the Role of the Tumor Microenvironment in Breast Cancer Progression”. Journal of Cancer Research and Clinical Oncology, 150.2 (2024): 345-359.
12. Li Y., et al. “Targeting Cancer Stem Cells in Breast Cancer: Current Strategies and Future Directions”. Clinical Cancer Research4 (2024): 1002-1015.
13. Patel KR., et al. “The Role of MicroRNAs in Breast Cancer: Mechanisms and Therapeutic Potential”. Journal of Molecular Medicine3 (2024): 457-473.
14. Cavalcante RC., et al. “Quality of life and adherence to treatment in cancer patients: A systematic review”. Supportive Care in Cancer8 (2021): 4313-4321.
15. Nguyen TT., et al. “Advancements in Personalized Medicine for Breast Cancer: Integrating Genomics and Clinical Practice”. Breast Cancer Research and Treatment2 (2024): 267-284.
16. Arteaga CL and Engelman JA. “ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-based Cancer Therapeutics”. Cancer Cell3 (2014): 282-303.
17. DiSipio T., et al. “Incidence of Unilateral Arm Lymphedema After Breast Cancer: A Systematic Review and Meta-analysis”. The Lancet Oncology6 (2013): 500-515.
18. Harbeck N., et al. “Breast Cancer”. Nature Reviews Disease Primers1 (2019): 66.
19. Williams D and Patel R. “The Impact of Chemotherapy Toxicity on Quality of Life in Breast Cancer Patients”. Breast Cancer Research and Treatment3 (2019): 457-470.
20. Kuter DJ. “Managing Thrombocytopenia Associated with Cancer Chemotherapy”. Oncologist6 (2015): 536-549.
21. Andreyev J., et al. “Guidance on the Management of Diarrhea During Cancer Treatment”. The Lancet Oncology10 (2014): e447-e460.
22. Boyette-Davis JA., et al. “Peripheral Neuropathy in Taxane-based Chemotherapy: Challenges and Perspectives”. Pain Management6 (2011): 527-539.
23. Cardinale D., et al. “Anthracycline-induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy”. Journal of the American College of Cardiology3 (2010): 213-220.
24. Kirova YM and Louis E. “Radiotherapy for Breast Cancer: Clinical Outcomes and Future Directions”. European Journal of Surgical Oncology5 (2015): 651-658.
25. Rojas C and Huerta A. “Quality of Life in Breast Cancer Patients Undergoing Radiotherapy: The Impact of Treatment”. Quality of Life Research7 (2015): 1715-1721.
26. Coleman RE and McCloskey EV. “Bone Health in Patients with Breast Cancer: A Review of the Literature”. The Lancet Oncology 10 (2014): e451-e461.
27. Tsimafeyeu I and Shcherbakov D. “The Role of Genomic Profiling in Breast Cancer: Identifying Resistance Mechanisms”. Breast Cancer Research and Treatment2 (2020): 239-253.
28. McGranahan N and Swanton C. “Deciphering the Evolutionary Dynamics of Cancer Genomes”. Nature Reviews Genetics 7 (2017): 341-354.
29. Merenbloom A and Koutsoumanis D. “Mechanisms of Acquired Resistance to Endocrine Therapy in Estrogen Receptor-Positive Breast Cancer: A Review”. Cancer Treatment Reviews 66 (2018): 1-9.
30. Kearns DR and Chen Y. “Mechanisms of Drug Resistance in Cancer: Current Strategies and Future Perspectives”. Cancer Treatment Reviews 76 (2019): 19-28.
31. Khan S., et al. “The role of drug resistance in breast cancer treatment: A review”. Journal of Clinical Medicine15 (2021): 3304.
32. Pusztai L and Isakoff SJ. “Clinical Trials in Triple-Negative Breast Cancer: Opportunities and Challenges”. Clinical Cancer Research11 (2014): 2709-2717.
33. Van Allen EM., et al. “Clinical analysis and interpretation of cancer genome data”. Journal of Clinical Oncology6 (2015): 662-666.
34. Huang Y., et al. “Radiation therapy for breast cancer: Current perspectives and future directions”. Frontiers in Oncology 10 (2020): 511.
35. Bardia A., et al. “Neoadjuvant chemotherapy and the role of hormone therapy in breast cancer”. The Lancet Oncology10 (2016): e441-e452.
36. Dehaini D and Liu H. “Targeting Tumor Microenvironments with Nano-Engineered Therapeutics: Strategies and Applications”. Biomaterials Science10 (2017): 1900-1910.
37. Singh A and Ladhani N. “Nanoscale Drug Delivery Systems: A New Era in Cancer Treatment”. Nanomedicine20 (2018): 2471-2490.
38. Zhan C and Hu C. “The Role of EPR Effect in Nanoparticle-Based Cancer Therapy”. Cancer Nanotechnology4 (2019): 273-286.
39. Khedher NB and Ferhi N. “Targeted Drug Delivery Systems for Cancer Treatment: Advances and Challenges”. Frontiers in Pharmacology 10 (2019): 138.
40. Sinha R and Ghosh S. “Nanoparticle-Mediated Combination Therapy: A Paradigm Shift in Cancer Treatment”. Expert Review of Anticancer Therapy1 (2019): 37-50.
41. Gopalakrishnan R and Iyer M. “Nanoparticle-Mediated Inhibition of Drug Efflux Pumps in Multidrug-Resistant Tumors”. Pharmaceutical Research6 (2018): 117.
42. Shi J and Kantoff PW. “Nanomedicine in Cancer Therapy: Challenges and Opportunities”. Nature Reviews Cancer1 (2017): 20-37.
43. Wang X and Zhang H. “Personalized Nanomedicine: Promising Therapeutic Approaches with Nanotechnology”. Journal of Controlled Release 282 (2018): 94-113.
44. Bae JM and Lee H. “Metastatic Triple-Negative Breast Cancer: Clinical and Pathological Features and Treatment Strategies”. Breast Cancer Research and Treatment2 (2016): 263-276.
45. Barenholz Y. “Doxil^®-the first FDA-approved nano-drug: Lessons learned”. Journal of Controlled Release 2 (2012): 117-134.
46. Pérez-Hernández M., et al. “Lipid-based nanocarriers for the delivery of RNA-based therapeutics”. Molecular Therapy - Nucleic Acids 7 (2017): 228-236.
47. Feng Y., et al. “Nanoparticle-based drug delivery systems for cancer therapy: A review”. Frontiers in Pharmacology 12 (2021): 694452.
48. Shen J., et al. “Advances in the application of nanoparticles for the treatment of cancer”. Frontiers in Pharmacology 12 (2021): 623843.
49. Yin Y., et al. “Advances in the design of nanoparticles for targeted drug delivery in cancer therapy”. Molecular Pharmaceutics3 (2020): 1001-1016.
50. Wong CS., et al. “Nanoparticles for cancer therapy: Progress and challenges”. Frontiers in Pharmacology 11 (2020): 1033.
51. Jiang Y., et al. “Advances in nanotechnology-based strategies for breast cancer therapy”. Journal of Nanobiotechnology1 (2021): 86-97.
52. Mansoori B., et al. “Nano-based delivery systems for breast cancer chemotherapy: Recent advances and future challenges”. Journal of Nanobiotechnology1 (2021): 68-79.
53. Benson AB., et al. “The role of palliative care in cancer management”. The Oncologist4 (2009): 420-426.
54. Guo S., et al. “Advances in cancer nanomedicine: From diagnostics to therapeutics”. Frontiers in Pharmacology 12 (2021): 675146.
55. Saha S., et al. “Targeted delivery of therapeutics in cancer treatment: A review on nanotechnology approaches”. Current Drug Delivery4 (2018): 510-522.
56. Rosenblum D., et al. “Progress and challenges towards targeted delivery of cancer therapeutics”. Nature Communications1 (2018): 1416.
57. Zhou Y., et al. “Advances in nanotechnology for the treatment of breast cancer: A review”. Journal of Drug Targeting1 (2021): 1-13.
58. S. Food and Drug Administration (FDA). 2020 Annual Report: Advancing health through innovation (2020).

Citation

Citation: Syamantak Mani Tripathi., et al. “Precision Targeting of Breast Cancer with Engineered Nano- Therapeutics and Breakthroughs”.Acta Scientific Medical Sciences 8.12 (2024): 155-171.

Copyright

Copyright: © 2024 Syamantak Mani Tripathi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.